Long term results of growth hormone treatment in France in children of short stature: population, register based study

Coste, Joёl; Letrait, Muriel; Carel, Jean Claude; Tresca, Jean Pierre; Chatelain, Pierre; Rochiccioli, P; Chaussain, J L; Job, J C

doi:10.1136/bmj.315.7110.708

Cited by 72 publications

(52 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In France, from 1973 onwards, the distribution of GH, initially extracted but later recombinant, has been organized nationwide under the medical control of Association France-Hypophyse, as previously described (3). All deliveries of GH were registered and data on treated children were recorded on standardized charts.…”

Section: Methodsmentioning

confidence: 99%

“…Long-term results of this treatment are now becoming available and remain disappointing, with adult heights often 2 S.D. below the population's mean (1)(2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

“…However, several other factors have been identified in multivariate analyses as influencing final outcome, including target height, height and bone age (BA) deficit at the start of treatment, height at the start of puberty (4,5) and age at the onset of treatment, earlier treatment resulting in higher adult heights (3,4,(7)(8)(9). These findings probably reflect a wide heterogeneity of the treated patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long-term results of GH therapy in GH-deficient children treated before 1 year of age

Huet

Jc²,

Nivelon³

et al. 1999

European Journal of Endocrinology

View full text Add to dashboard Cite

Objectives: To evaluate the long-term effects of GH therapy in early diagnosed GH-deficient patients treated before 1 year of age. Study design: We studied all 59 patients (33 males) recorded by Association France-Hypophyse and treated with GH (0.50 Ϯ 0.15 IU/kg (S.D.) per week) before 1 year of age. Clinical presentation and growth parameters under GH treatment were analyzed. Results: Neonatal manifestations of hypopituitarism were frequent: hypoglycemia (n ¼ 50), jaundice (n ¼ 25) and micropenis (n ¼ 17/33). Although birth length was moderately reduced (¹0.9 Ϯ 1.4), growth retardation at diagnosis (5.8 Ϯ 3.8 months) was severe (¹3.5 Ϯ 1.9 standard deviation scores (SDS)). Fifty patients (85%) had thyrotropin and/or corticotropin deficiency. After a mean duration of GH therapy of 8.0 Ϯ 3.6 years, change in height SDS was þ3:11 Ϯ 2:06 S.D., exceeding 4 SDS in 19 patients. Only 9 patients (15%) did not reach a height of ¹2 S.D. for chronological age and 20 patients (34%) exceeded their target height. Pretreatment height SDS was independently associated with total catch-up growth. Conclusion: Conventional doses of GH allow normalization of height in patients with early GH deficiency and treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Long-term results of this treatment are now becoming available and remain disappointing, with adult heights often 2 S.D. below the population's mean (1)(2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term results of GH therapy in GH-deficient children treated before 1 year of age

Huet

Jc²,

Nivelon³

et al. 1999

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Tedaviye başlama yaşı: Erken tanının, büyüme yanıtı üzerine olumlu etkisi yüksektir (16)(17)(18)(19) . Tanı ne kadar erken konur, tedavi ne kadar erken yaşta başla-nırsa yanıt daha iyi olmaktadır.…”

Section: Büyüme Hormonu Yerine Koyma Tedavisinin Hedefleri Ve Tedavi unclassified

Optimizing growth hormone threapy in chilhood growth hormone defiency

Darendelıler¹

2016

Cocuk Dergisi

View full text Add to dashboard Cite

show abstract

“…Yet, the diagnostic process is strainful, in terms of cost, staff, and being time-intensive, as to current knowledge identification of NSD is only possible by measuring spontaneous GH-secretion for 24 or 12 hours [3,6]. Moreover there is no general consensus which parameters (e.g., number and maximal amplitude of peaks, maximal and mean GHsecretion, and area under the curve) should be used for analysis of spontaneous GH-secretion [3,[6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Prepubertal Patients with Suspected Neurosecretory Dysfunction of Growth Hormone Secretion: Diagnostic Steps and Treatment Response

Sydlik

Weissenbacher

Roeb

et al. 2017

Advances in Endocrinology

View full text Add to dashboard Cite

Background and Aims. Existence and diagnostic procedures of neurosecretory dysfunction of growth hormone (NSD) are still a matter of debate. The aim of our study was (a) to find out if prediagnostic auxological and laboratory data could serve as an indicator for pathologic and normal spontaneous GH-secretion and (b) to evaluate the response to GH-therapy in NSD-patients. Methods. Of 90 children (unicentric study) with normal response to GH-stimulation tests, in whom 12-hour night profiles for GHsecretion were performed, 49 were diagnosed with NSD (NSD group). Their auxologic data, IGF-I/IGFBP3-levels as well as the night profiles, were analysed and compared to those of the non-NSD group. Additionally, follow-up auxological data of the GH-treated NSD-patients were collected. Results. Prediagnostic auxologic and laboratory data did not differ between the two groups. Instead, for all analysed criteria of spontaneous GH-secretion (number of peaks, maximal and mean secretion) a significant difference was found. Children with NSD showed a good response to GH-treatment after 1 (ΔH-SDS +0,77 ± 0,48) as well as 4 years (+1,51 ± 0,75). Conclusion. According to our results, analysing spontaneous GH-secretion remains the only method to identify NSD. Yet, as response to GH-treatment is comparable to results in idiopathic GHD, it is worth to consider this diagnosis.

show abstract

Long term results of growth hormone treatment in France in children of short stature: population, register based study

Abstract: Objectives: To describe the growth of children treated with growth hormone and to evaluate the prognostic factors for height at the end of treatment. Design: Register based cohort study. Setting: French national register of all children treated with growth hormone.

Cited by 72 publications

References 27 publications

Long-term results of GH therapy in GH-deficient children treated before 1 year of age

Long-term results of GH therapy in GH-deficient children treated before 1 year of age

Optimizing growth hormone threapy in chilhood growth hormone defiency

Evaluation of Prepubertal Patients with Suspected Neurosecretory Dysfunction of Growth Hormone Secretion: Diagnostic Steps and Treatment Response

Contact Info

Product

Resources

About